Compare NMIH & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMIH | AAPG |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2013 | N/A |
| Metric | NMIH | AAPG |
|---|---|---|
| Price | $37.26 | $24.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $43.00 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 343.9K | 1.6K |
| Earning Date | 04-28-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.06 | N/A |
| EPS | ★ 4.92 | N/A |
| Revenue | ★ $706,440,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.34 | $368.64 |
| P/E Ratio | $7.56 | ★ N/A |
| Revenue Growth | ★ 8.52 | N/A |
| 52 Week Low | $32.71 | $17.56 |
| 52 Week High | $43.20 | $48.45 |
| Indicator | NMIH | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 38.20 | 48.01 |
| Support Level | $36.78 | $23.12 |
| Resistance Level | $37.66 | $25.47 |
| Average True Range (ATR) | 0.74 | 0.77 |
| MACD | -0.16 | 0.20 |
| Stochastic Oscillator | 25.54 | 67.06 |
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.